Epidemiology of Carbapenem-Resistant <i>Enterobacteriaceae</i> Bacteremia in Gyeonggi Province, Republic of Korea, between 2018 and 2021
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Seung Hye | - |
dc.contributor.author | Kim, Chan Hee | - |
dc.contributor.author | Lee, Hee Young | - |
dc.contributor.author | Park, Kun Hee | - |
dc.contributor.author | Han, Su Ha | - |
dc.date.accessioned | 2023-12-14T06:30:57Z | - |
dc.date.available | 2023-12-14T06:30:57Z | - |
dc.date.issued | 2023-08 | - |
dc.identifier.issn | 2079-6382 | - |
dc.identifier.issn | 2079-6382 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/25427 | - |
dc.description.abstract | The incidence of carbapenem-resistant Enterobacteriaceae (CRE) has been increasing since 2008, with Gyeonggi Province in South Korea being particularly vulnerable due to its large number of healthcare facilities. This study examines the trends of CRE occurrence in Gyeonggi Province over the past four years and the epidemiological characteristics of the infected patients. Patients with positive CRE blood cultures admitted to healthcare facilities in Gyeonggi Province from January 2018 to December 2021 were evaluated in this study. Risk factors for CRE-related death were analyzed using data from patients who died within 30 days of the last blood sampling. Older adults aged 70 years and above constituted the majority of patients with CRE bacteremia. Antibiotic use did not significantly affect mortality risk. Non-survivors were more common in tertiary hospitals and intensive care units and included patients with hypertension, malignant tumors, and multiple underlying diseases. Klebsiella pneumoniae was the most common CRE strain, with Klebsiella pneumoniae carbapenemase being the predominant carbapenemase. Our study suggests the endemicity of CRE in Gyeonggi Province and highlights the increasing isolation of CRE strains in South Korean long-term care hospitals within the province. Further, infection control measures and government support specific to each healthcare facility type are crucial. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI | - |
dc.title | Epidemiology of Carbapenem-Resistant <i>Enterobacteriaceae</i> Bacteremia in Gyeonggi Province, Republic of Korea, between 2018 and 2021 | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3390/antibiotics12081286 | - |
dc.identifier.scopusid | 2-s2.0-85168997389 | - |
dc.identifier.wosid | 001056137700001 | - |
dc.identifier.bibliographicCitation | ANTIBIOTICS-BASEL, v.12, no.8 | - |
dc.citation.title | ANTIBIOTICS-BASEL | - |
dc.citation.volume | 12 | - |
dc.citation.number | 8 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | RISK-FACTORS | - |
dc.subject.keywordPlus | ACQUISITION | - |
dc.subject.keywordPlus | PREVALENCE | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.subject.keywordPlus | COMMUNITY | - |
dc.subject.keywordAuthor | carbapenem-resistant Enterobacteriaceae (CRE) | - |
dc.subject.keywordAuthor | carbapenemase-producing Enterobacteriaceae (CPE) | - |
dc.subject.keywordAuthor | non-survivors | - |
dc.subject.keywordAuthor | epidemiologic characteristics | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.